Abstract 3381: Establishment of a novel multi-omic biomarker panel in cyst fluid and blood for stratifying patient risk of pancreatic cancer

• Published in: Cancer research (Chicago, Ill.) Ill.), 2022-06, Vol.82 (12_Supplement), p.3381-3381
• Main Authors: Kane, Laura E., Mellotte, Gregory S., Lyons, Rebecca G., Mylod, Eimear, Marcone, Simone, Ridway, Paul F., MacCarthy, Finbar, Conlon, Kevin C., Lysaght, Joanne, Ryan, Barbara M., Maher, Stephen G.
• Format: Article
• Language: English
• ISSN: 1538-7445; 1538-7445
• DOI: 10.1158/1538-7445.AM2022-3381

Introduction: Pancreatic cancer was responsible for almost 500,000 deaths globally in 2020 according to GLOBOCAN. Pancreatic cystic lesions (PCLs) are fluid-filled protrusions either on or inside the pancreas and can either be benign or pre-malignant. Current clinical guidelines to risk stratify PCL patients are imperfect. Multi-omic profiling of pancreatic cyst fluid (PCF) could aid in the identification of a novel biomarker panel to improve PCL risk stratification. Methods: PCF was collected from 40 patients by EUS-FNA, with matched serum collected prior to EUS. Patients were stratified using the 2018 European evidence-based guidelines into low-risk (n=15), high risk (n=15) and no-risk or pseudocyst (n=10). PCF was sonicated and subsequently processed using an SP3 paramagnetic bead protocol prior to LC-MS. MS-generated LFQ intensity data were analyzed in Perseus (v1.6.13.0) and STRING (v11.5). HTG microRNA whole transcriptome sequencing was run on whole PCF. MiRNA sequencing data were analyzed using HTG EdgeSeq Reveal (v3.1.0). Spearman correlations were generated using R packages ‘Hmisc’ (v4.5-0) and ‘corrplot’ (v0.90). Results: MS-analysis of PCF revealed 8 proteins to be significantly upregulated in high-risk compared to low-risk (p